Novel spherical lactose produced by solid state crystallisation as a carrier for aerosolised salbutamol sulphate, beclomethasone dipropionate and fluticasone propionate

The purpose of the present work was to engineer lactose carrier particles for inhalation using a solid-state crystallisation amorphous spray dried approach. A suspension contacted with hot ethanol 10 and 30 s produce spherical (ESDL10) (ESDL30) different degrees crystallinity, particle size, controlled surface rugosity. Lactohale® (control) engineered (ESDL) were characterised by Scanning Electron Microscopy, X-ray Powder Diffraction Tribo-electrification. mixed separately salbutamol sulphate (SS), beclomethasone dipropionate (BDP) fluticasone propionate (FP) each formulation assessed drug content uniformity, segregation after tribo-electrification deposition Andersen Cascade Impactor (ACI). showed highest but opposite affinity electrical charges compared lactose. greatest variation in uniformity SS lesser extent BDP FP, whereas ESDL carriers produced an acceptable uniform mix all drugs. SS-Lactohale® up 119-fold comparison that observed SS-engineered ESDL10 promoted better both FP least FPD three Therefore, production crystalline texture, size crystallinity is achievable solid state DPIs, whilst providing less consistent fine dose lungs in-vitro hydrophilic hydrophobic